PRINTABLE SUMMARY
Before You Spend Money on Peptides
A clear starting point for evaluating peptide claims.
AI-assisted editorial edition · Independent clinical review pending.
Before you read
Educational source reading for adults, not diagnosis, prescription or a personal treatment plan. Do not start, stop or change treatment because of this guide. Discuss treatment, medicines and product questions with a qualified clinician and pharmacist.
What this edition can and cannot answer
A selected-source introduction to matching studies to product claims and preparing informed questions
- A study must match the actual substance, route, population, comparator and outcome before its conclusion can support a claim.
- Analytical quality, clinical benefit, safety and regulatory status answer different questions. A worksheet does not establish that a treatment is suitable for you.
- The selected-source introduction retains its October 7, 2026 evidence scope with October 27 source annotations; independent review remains pending.
SECTION 01
Before you buy: your claim-reading sheet
Write your question in one sentence: “For someone with my condition, does this exact treatment improve this outcome compared with the alternatives?” You do not need technical language to ask it.
| Check | Question |
|---|---|
| Molecule | Was the exact substance studied? |
| Route | Was it used in the same way? |
| Population | Who or what was studied? |
| Comparison | What was it compared with? |
| Outcome | Was the advertised result measured? |
A product-quality certificate cannot establish a clinical benefit. A short report without recorded side effects cannot establish safety for everyone. Compounded drugs are not FDA-approved. [1] [2]
FOLLOW THE EVIDENCE
Sources and reading limits
FDA. Evaluation of BPC-157-related bulk drug substances (2026)
Regulatory assessment
PDF pp. 8-9 and safety/conclusion sections; advisory briefing, not a final approval
FDA. Compounding and the FDA: Questions and Answers
Regulatory explanation
Sections: compounded drugs, approval and risks; official snapshot checked 27 October 2026; content current 16 September 2025
0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution in Neurotrophic Keratopathy (2023)
Randomized human eye-disease trial
Physical PDF pp. 3-5 and 11-14; Table 2 p. 5; registry/supplement checked 27 October 2026; day-36 conflict unresolved
Edition and corrections
Web reading edition: 4 November 2026. Manuscript prepared: 2026-11-04. This web-format update does not represent a new literature search or completed clinical review.
Edition: before-you-buy-2026-11-04-format-draft
Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.
Report a correction →